Sign In
Buy HRMY
$32.10
+1.19 (+3.85%)
At Close: Jun 03, 2026
Harmony Biosciences: In Harmony
05:50am, Friday, 23'rd Sep 2022
Harmony Biosciences has seen a strong performance of its WAKIX drug since it went public in 2020. This run up made that shares have done quite alright, vastly outperforming most IPOs of the time.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
08:05am, Wednesday, 17'th Aug 2022
PLYMOUTH MEETING, Pa. , Aug. 17, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company focused on delivering innovative therapie
6 Analysts Have This to Say About Harmony Biosciences
08:05pm, Wednesday, 03'rd Aug 2022 Benzinga
Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
2
0
0
L
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
02:38pm, Wednesday, 03'rd Aug 2022 Benzinga
Upgrades
Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2022 Earnings Call Transcript
05:00pm, Tuesday, 02'nd Aug 2022 The Motley Fool
HRMY earnings call for the period ending June 30, 2022.
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
12:45pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 42.50% and 7.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
11:30am, Tuesday, 02'nd Aug 2022 GlobeNewswire Inc.
WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021
Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q2 2022 Results - Earnings Call Transcript
11:07am, Tuesday, 02'nd Aug 2022
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John Jacobs - President and CEO Jeffrey Dierks -
Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat
09:52am, Tuesday, 02'nd Aug 2022
Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged. The post Harmony Biosciences Makes Leap Out Of Buy Zone Afte
HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS
08:05am, Tuesday, 19'th Jul 2022
PLYMOUTH MEETING, Pa. , July 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercial
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
02:07pm, Wednesday, 13'th Jul 2022 Benzinga
Upgrades
For The Shyft Group Inc (NASDAQ:SHYF), DA Davidson upgraded the previous rating of Neutral to Buy. Shyft Group earned $0.06 in the first quarter, compared to $0.36 in the year-ago quarter. Th
Investors Are Paying Attention to This Pharma That Is Gaining Speed
02:15pm, Friday, 08'th Jul 2022 The Motley Fool
Can turning one product into a portfolio of products result in revenue magic?
Investors Are Paying Attention to This Pharma That Is Gaining Speed
10:15am, Friday, 08'th Jul 2022
Can turning one product into a portfolio of products result in revenue magic?
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades
For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
